D2 dopamine receptor gene (DRD2) Taq1A (rs1800497) affects bone density

Area of Science:

• Neuroscience
• Genetics
• Orthopedics

Background:

• Schizophrenia is associated with reduced bone mineral density (BMD).
• Genetic factors influencing antipsychotic activity may impact BMD, especially with long-term treatment.
• Limited research exists on the genetic underpinnings of low BMD in schizophrenia patients.

Purpose of the Study:

• To investigate the association between the dopamine D2 receptor (DRD2) gene Taq1A (rs1800497) polymorphism and BMD in chronic schizophrenia patients.
• To explore the role of specific DRD2 genotypes in bone health within this population.

Main Methods:

• Recruited 47 schizophrenia patients and 39 healthy controls.
• Measured BMD using dual-energy X-ray absorptiometry (DEXA).
• Genotyped the DRD2 rs1800497 polymorphism via polymerase chain reaction-Restriction Fragment Length Polymorphism (PCR-RFLP).

Main Results:

• Participants with the DRD2 rs1800497(T;T) genotype exhibited significantly lower DEXA T and Z scores compared to those with (C;T) and (C;C) alleles (p=0.008, p=0.003).
• Within the schizophrenia group, the (T;T) genotype was associated with lower DEXA Z scores (p=0.045).

Conclusions:

• The DRD2 rs1800497(T;T) genotype is associated with lower bone mineral density.
• Genetic variations, specifically in the DRD2 gene, should be considered a potential risk factor for reduced BMD in schizophrenia.